Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies.
Following long-term infection with virus derived from the pathogenic GL8 molecular clone of feline immunodeficiency virus (FIV), a range of viral variants emerged with distinct modes of interaction with the viral receptors CD134 and CXCR4, and sensitivities to neutralizing antibodies. In order to assess whether this viral diversity would be maintained following subsequent transmission, a synthetic quasispecies was reconstituted comprising molecular clones bearing envs from six viral variants and its replicative capacity compared in vivo with a clonal preparation of the parent virus. Infection with either clonal (Group 1) or diverse (Group 2) challenge viruses, resulted in a reduction in CD4+ lymphocytes and an increase in CD8+ lymphocytes. Proviral loads were similar in both study groups, peaking by 10 weeks post-infection, a higher plateau (set-point) being achieved and maintained in study Group 1. Marked differences in the ability of individual viral variants to replicate were noted in Group 2; those most similar to GL8 achieved higher viral loads while variants such as the chimaeras bearing the B14 and B28 Envs grew less well. The defective replication of these variants was not due to suppression by the humoral immune response as virus neutralising antibodies were not elicited within the study period. Similarly, although potent cellular immune responses were detected against determinants in Env, no qualitative differences were revealed between animals infected with either the clonal or the diverse inocula. However, in vitro studies indicated that the reduced replicative capacity of variants B14 and B28 in vivo was associated with altered interactions between the viruses and the viral receptor and co-receptor. The data suggest that viral variants with GL8-like characteristics have an early, replicative advantage and should provide the focus for future vaccine development.
MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom. rian.willett@glasgow.ac.uk
Brian J
BJ
Willett
Martin
M
Kraase
Nicola
N
Logan
Elizabeth
E
McMonagle
Mariana
M
Varela
Margaret J
MJ
Hosie
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D002415:Cats; D002460:Cell Line; D018604:Epitope Mapping; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000276:immunology; D015686:Gene Products, env / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000472:pathogenicity / Q000502:physiology*; D016180:Lentivirus Infections / Q000276:immunology / Q000821:virology*; D011533:Proviruses; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D019562:Viral Load; D014779:Virus Replication
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D018984:Epitopes, T-Lymphocyte; D015686:Gene Products, env; D019718:Receptors, CXCR4